Browsing by Author "Kirklin, James K."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Post-transplant outcomes in pediatric ventricular assist device patients: A PediMACS–Pediatric Heart Transplant Study linkage analysis
    (Elsevier, 2017) Sutcliffe, David L.; Pruitt, Elizabeth; Cantor, Ryan S.; Godown, Justin; Lane, John; Turrentine, Mark W.; Law, Sabrina P.; Lantz, Jodie L.; Kirklin, James K.; Bernstein, Daniel; Blume, Elizabeth D.; Surgery, School of Medicine
    Background Pediatric ventricular assist device (VAD) support as bridge to transplant has improved waitlist survival, but the effects of pre-implant status and VAD-related events on post-transplant outcomes have not been assessed. This study is a linkage analysis between the PediMACS and Pediatric Heart Transplant Study databases to determine the effects of VAD course on post-transplant outcomes. Methods Database linkage between October 1, 2012 and December 31, 2015 identified 147 transplanted VAD patients, the primary study group. The comparison cohort was composed of 630 PHTS patients without pre-transplant VAD support. The primary outcome was post-transplant survival, with secondary outcomes of post-transplant length of stay, freedom from infection and freedom from rejection. Results At implant, the VAD cohort was INTERMACS Profile 1 in 33 (23%), Profile 2 in 89 (63%) and Profile 3 in 14 (10%) patients. The VAD cohort was older, larger, and less likely to have congenital heart disease (p < 0.0001). However, they had greater requirements for inotrope and ventilator support and increased liver and renal dysfunction (p < 0.0001), both of which normalized at transplant after device support. Importantly, there were no differences in 1-year post-transplant survival (96% vs 93%, p = 0.3), freedom from infection (81% vs 79%, p = 0.9) or freedom from rejection (71% vs 74%, p = 0.87) between cohorts. Conclusions Pediatric VAD patients have post-transplant outcomes equal to that of medically supported patients, despite greater pre-implant illness severity. Post-transplant survival, hospital length of stay, infection and rejection were not affected by patient acuity at VAD implantation or VAD-related complications. Therefore, VAD as bridge to transplant mitigates severity of illness in children.
  • Thumbnail Image
    Item
    Time-Related Risk of Pulmonary Conduit Re-replacement: A Congenital Heart Surgeons’ Society Study
    (Elsevier, 2021-06) Callahan, Connor P.; Jegatheeswaran, Anusha; Blackstone, Eugene H.; Karamlou, Tara; Baird, Christopher W.; Ramakrishnan, Karthik; Herrmann, Jeremy L.; Brown, John W.; Nelson, Jennifer S.; Polimenakos, Anastasios C.; Lambert, Linda M.; Eckhauser, Aaron W.; Kirklin, James K.; DeCampli, William M.; Aghaei, Nabi; St. Louis, James D.; McCrindle, Brian W.; Medicine, School of Medicine
    Background Patients receiving a right ventricle to pulmonary artery conduit (PC) in infancy will require successive procedures or replacements, each with variable longevity. We sought to identify factors associated with time-related risk of a subsequent surgical replacement (PC3) or transcatheter pulmonary valve insertion (TPVI) after a second surgically placed PC (PC2). Methods From 2002 to 2016, 630 patients from 29 Congenital Heart Surgeons’ Society member institutions survived to discharge after initial valved PC insertion (PC1) at age ≤ 2 years. Of those, 355 underwent surgical replacement (PC2) of that initial conduit. Competing risk methodology and multiphase parametric hazard analyses were used to identify factors associated with time-related risk of PC3 or TPVI. Results Of 355 PC2 patients (median follow-up, 5.3 years), 65 underwent PC3 and 41 TPVI. Factors at PC2 associated with increased time-related risk of PC3 were smaller PC2 Z score (hazard ratio [HR] 1.6, P < .001), concomitant aortic valve intervention (HR 7.6, P = .009), aortic allograft (HR 2.2, P = .008), younger age (HR 1.4, P < .001), and larger Z score of PC1 (HR 1.2, P = .04). Factors at PC2 associated with increased time-related risk of TPVI were aortic allograft (HR: 3.3, P = .006), porcine unstented conduit (HR 4.7, P < .001), and older age (HR 2.3, P = .01). Conclusions Aortic allograft as PC2 was associated with increased time-related risk of both PC3 and TPVI. Surgeons may reduce risk of these subsequent procedures by not selecting an aortic homograft at PC2, and by oversizing the conduit when anatomically feasible.
  • Thumbnail Image
    Item
    Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: Readmissions after LVAD
    (Elsevier, 2022) Shah, Palak; Yuzefpolskaya, Melana; Hickey, Gavin W.; Breathett, Khadijah; Wever-Pinzon, Omar; Khue-Ton, Van; Hiesinger, William; Koehl, Devin; Kirklin, James K.; Cantor, Ryan S.; Jacobs, Jeffrey P.; Habib, Robert H.; Pagani, Francis D.; Goldstein, Daniel J.; Medicine, School of Medicine
    The twelfth annual report from The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) highlights outcomes for 26 688 continuous-flow left ventricular assist device (LVAD) patients over the past decade (2011-2020). In 2020, we observed the largest drop in yearly LVAD implant volumes since the registry's inception, which reflects the effects of the COVID-19 pandemic on cardiac surgical volumes in the United States. The 2018 heart transplant allocation policy change in the United States continues to affect LVAD implantation volumes and device strategy, with 78.1% of patients now receiving LVAD implants as destination therapy. Despite an older and sicker patient cohort, survival in the recent era (2016-2020) at 1 and 2 years continues to improve at 82.8% and 74.1%. Patient adverse event profile has also improved in the recent era, with significant reductions in stroke, gastrointestinal bleeding, infection, and device malfunction/pump thrombosis. Finally, we review the burden of readmissions after LVAD implant and highlight an opportunity to improve patient outcomes by reducing this frequent and vexing problem.